A new experimental drug from Pfizer has proven to eliminate progression of incurable breast cancer for over a two year period, says research that was recently published. PD 0332991 was distributed to patients along with the drug Femara, manufactured by Novartis.
Results of the study revealed that there was no advancement in tumors on average for 26 months in patients taking both PD 0332991 and Femara, compared to just 7 months for patients who were only administered Femara. The new drug is only in the second of three required stages of trials that the U.S. Food and Drug Administration requires in order to grant its approval.
The new drug is the first of a new group that function by inhibiting imperative protein in the production cycle of cancer cells. The recent findings are of great significance due to the large difference in advantage time and the comparative safety of the treatment. Involved in the study were 165 patients with metastatic cancer. It was a small trial and a larger population one needs to be performed to help confirm the results from the first trial.
Women participating in the just completed study had tumors that had been stimulated by the hormone estrogen. These are the most common of all forms of breast cancer and all of the women suffered from metastatic cancer, which means the cancer spread to another part of their body and had been declared incurable.
Breast cancer in women is the second most fatal form of cancer. In the U.S., it is estimated that over 230,000 women will be diagnosed with the disease in 2012 and close to 40,000 will lose their life.